Biolexis Therapeutics Presents First-in-Human Phase 1a Data for BLX-7006, an Oral Small-Molecule GLP-1 Receptor Agonist with a Structurally Distinct Allosteric Mechanism, at ObesityWeek® 2026
Tremonton
Archived
•
November 12, 2026
•
HIGHLIGHTS• Differentiated mechanism: Structural and preclinical studies demonstrate activation through a distinct allosteric binding site and potentiation of endogenous GLP-1 signaling.• Favorable safety & tolerability: BLX-7006 was generally well tolerated at oral doses up to 150 mg, with no serious…
Source: The Leader (Tremonton) | https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



